An observational study in Liver Disease, sponsored by University Hospital, Strasbourg, France. Status unknown at 2 sites in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2009-04-27.
Sponsored by University Hospital, Strasbourg, France · Observational
Non alcoholic fatty liver diseases (NAFLD) are represented by two main pathological conditions, hepatic steatosis (HS) and non alcoholic steatohepatitis (NASH), which are characterized by the accumulation of fat in the liver. The diagnosis of these two entities is achieved by histology and neither imaging nor biochemical markers are accurate enough to discriminate them. At the contrary of HS, NASH features hepatocyte necrosis, inflammation and fibrosis of variable intensity that could progress and ultimately evolve to cirrhosis. Therefore, it is important to distinguish between HS and NASH in order to treat the patients accordingly. In this study, the investigators aim to understand the molecular mechanisms that govern the transition from benign steatosis to complicated NASH. The investigators will analyze by "Q-RT-PCR" and "DNA microarray" technologies in the liver of obese patients, the expression of genes that are susceptible to be involved in the pathogenesis of NAFLD and identify the potential signaling pathways responsible for the progression of the disease.
2,080 studies on the registry are indexed under Liver Diseases; 389 are open to participants now.
This study's planned enrollment of 90 is below the median of 167 across 681 observational studies indexed under Liver Diseases.
Browse Liver Diseases studies →University Hospital, Strasbourg, France is the lead sponsor of 960 studies on the registry; 336 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
Exclusion Criteria:
(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
Procedure: cholecystectomy or benign liver tumor removal
(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
Procedure: Bariatric surgery
(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
Procedure: Bariatric surgery
Gastric bypass.
cholecystectomy or benign liver tumor removal
This study is status unknown, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France